NewsBenzingaVor Bio公布TELIGAN 3期试验最终两年结果:评估泰它西普用于IgA肾病成人患者;TELIGAN达到B阶段主要终点 Vor Bio公布TELIGAN 3期试验最终两年结果:评估泰它西普用于IgA肾病成人患者;TELIGAN达到B阶段主要终点 Benzinga 2026.10.22 20:09 (GMT+0) Open on Benzinga Other news Freedom Broker Maintains Buy on XPeng, Lowers Price Target to $20 Plug Power Shares Slide Toward 52-Week Low Despite New 280-MW Texas Deal Nvidia Vs. Anthropic: Can the AI IPO Challenge Nvidia’s Dominance Across ETFs? Freedom Broker Maintains Buy on Allot, Lowers Price Target to $12.7 Freedom Broker Upgrades M-Tron Industries to Buy, Lowers Price Target to $84 As decision model use skyrockets, is customization is the next frontier?